Literature DB >> 16887988

Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1.

Robert W Carter1, Clare Thompson, Delyth M Reid, Simon Y C Wong, David F Tough.   

Abstract

Targeting of Ags and therapeutics to dendritic cells (DCs) has immense potential for immunotherapy and vaccination. Because DCs are heterogeneous, optimal targeting strategies will require knowledge about functional specialization among DC subpopulations and identification of molecules for targeting appropriate DCs. We characterized the expression of a fungal recognition receptor, DC-associated C-type lectin-1 (Dectin-1), on mouse DC subpopulations and investigated the ability of an anti-Dectin-1 Ab to deliver Ag for the stimulation of immune responses. Dectin-1 was shown to be expressed on CD8alpha-CD4-CD11b+ DCs found in spleen and lymph nodes and dermal DCs present in skin and s.c. lymph nodes. Injection of Ag-anti-Dectin-1 conjugates induced CD4+ and CD8+ T cell and Ab responses at low doses where free Ag failed to elicit a response. Notably, qualitatively different immune responses were generated by targeting Ag to Dectin-1 vs CD205, a molecule expressed on CD8alpha+CD4-CD11b- DCs, dermal DCs, and Langerhans cells. Unlike anti-Dectin-1, anti-CD205 conjugates failed to elicit an Ab response. Moreover, when conjugates were injected i.v., anti-Dectin-1 stimulated a much stronger CD4+ T cell response and a much weaker CD8+ T cell response than anti-CD205. The results reveal Dectin-1 as a potential targeting molecule for immunization and have implications for the specialization of DC subpopulations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16887988     DOI: 10.4049/jimmunol.177.4.2276

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

1.  Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.

Authors:  Eynav Klechevsky; Anne-Laure Flamar; Yanying Cao; Jean-Philippe Blanck; Maochang Liu; Amy O'Bar; Olivier Agouna-Deciat; Peter Klucar; Luann Thompson-Snipes; Sandra Zurawski; Yoram Reiter; A Karolina Palucka; Gerard Zurawski; Jacques Banchereau
Journal:  Blood       Date:  2010-06-07       Impact factor: 22.113

Review 2.  Targeting human dendritic cell subsets for improved vaccines.

Authors:  Hideki Ueno; Eynav Klechevsky; Nathalie Schmitt; Ling Ni; Anne-Laure Flamar; Sandra Zurawski; Gerard Zurawski; Karolina Palucka; Jacques Banchereau; Sangkon Oh
Journal:  Semin Immunol       Date:  2011-01-28       Impact factor: 11.130

3.  Concomitant activation and antigen uptake via human dectin-1 results in potent antigen-specific CD8+ T cell responses.

Authors:  Ling Ni; Ingrid Gayet; Sandra Zurawski; Dorothee Duluc; Anne-Laure Flamar; Xiao-Hua Li; Amy O'Bar; Sandra Clayton; Anna Karolina Palucka; Gerard Zurawski; Jacques Banchereau; SangKon Oh
Journal:  J Immunol       Date:  2010-08-20       Impact factor: 5.422

4.  Modifying Dendritic Cell Activation with Plasmonic Nano Vectors.

Authors:  Kieng Bao Vang; Ingrid Safina; Emilie Darrigues; Dmitry Nedosekin; Zeid A Nima; Waqar Majeed; Fumiya Watanabe; Ganesh Kannarpady; Rajshekhar A Kore; Daniel Casciano; Vladimir P Zharov; Robert J Griffin; Ruud P M Dings; Alexandru S Biris
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

5.  Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens.

Authors:  Louise J Young; Nicholas S Wilson; Petra Schnorrer; Adele Mount; Rachel J Lundie; Nicole L La Gruta; Brendan S Crabb; Gabrielle T Belz; William R Heath; Jose A Villadangos
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-31       Impact factor: 11.205

Review 6.  Improving vaccines by targeting antigens to dendritic cells.

Authors:  Ken Shortman; Mireille H Lahoud; Irina Caminschi
Journal:  Exp Mol Med       Date:  2009-02-28       Impact factor: 8.718

Review 7.  Controlling immune responses by targeting antigens to dendritic cell subsets and B cells.

Authors:  Craig P Chappell; Natalia V Giltiay; Christiane Dresch; Edward A Clark
Journal:  Int Immunol       Date:  2013-11-27       Impact factor: 4.823

Review 8.  Targeted antigen delivery to DEC-205⁺ dendritic cells for tolerogenic vaccination.

Authors:  Cathleen Petzold; Sonja Schallenberg; Joel N H Stern; Karsten Kretschmer
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 9.  Directing dendritic cell immunotherapy towards successful cancer treatment.

Authors:  Rachel Lubong Sabado; Nina Bhardwaj
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

10.  The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement.

Authors:  Irina Caminschi; Anna I Proietto; Fatma Ahmet; Susie Kitsoulis; Joo Shin Teh; Jennifer C Y Lo; Alexandra Rizzitelli; Li Wu; David Vremec; Serani L H van Dommelen; Ian K Campbell; Eugene Maraskovsky; Hal Braley; Gayle M Davey; Patricia Mottram; Nicholas van de Velde; Kent Jensen; Andrew M Lew; Mark D Wright; William R Heath; Ken Shortman; Mireille H Lahoud
Journal:  Blood       Date:  2008-07-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.